|
1
|
Jemal A, Bray F, Center MM, Ferlay J, Ward
E and Forman D: Global cancer statistics. CA Cancer J Clin.
61:69–90. 2011. View Article : Google Scholar
|
|
2
|
Hanahan D and Folkman J: Patterns and
emerging mechanisms of the angiogenic switch during tumorigenesis.
Cell. 86:353–364. 1996. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Amini A, Masoumi Moghaddam S, Morris DL
and Pourgholami MH: The critical role of vascular endothelial
growth factor in tumor angiogenesis. Curr Cancer Drug Targets.
12:23–43. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Arcondéguy T, Lacazette E, Millevoi S,
Prats H and Touriol C: VEGF-A mRNA processing, stability and
translation: a paradigm for intricate regulation of gene expression
at the post-transcriptional level. Nucleic Acids Res. 41:7997–8010.
2013.PubMed/NCBI
|
|
5
|
Ferrara N and Davis-Smyth T: The biology
of vascular endothelial growth factor. Endocr Rev. 18:4–25. 1997.
View Article : Google Scholar
|
|
6
|
Koukourakis MI, Papazoglou D,
Giatromanolaki A, Bougioukas G, Maltezos E and Sivridis E: VEGF
gene sequence variation defines VEGF gene expression status and
angiogenic activity in non-small cell lung cancer. Lung Cancer.
46:293–298. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Jin Q, Hemminki K, Enquist K, Lenner P,
Grzybowska E, Klaes R, Henriksson R, Chen B, Pamula J, Pekala W,
Zientek H, Rogozinska-Szczepka J, Utracka-Hutka B, Hallmans G and
Försti A: Vascular endothelial growth factor polymorphisms in
relation to breast cancer development and prognosis. Clin Cancer
Res. 11:3647–3653. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Celen O, Kahraman I, Yildirim E and
Berberoglu U: Correlation of vascular endothelial growth factor
(VEGF) and CEA with clinicopathological variables in colorectal
cancer patients. Neoplasma. 51:293–299. 2004.PubMed/NCBI
|
|
9
|
Shen YC, Hsu C and Cheng AL: Molecular
targeted therapy for advanced hepatocellular carcinoma: current
status and future perspectives. J Gastroenterol. 45:794–807. 2010.
View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Chen L, Shi Y, Jiang CY, Wei LX, Lv YL,
Wang YL and Dai GH: Coexpression of PDGFR-alpha, PDGFR-beta and
VEGF as a prognostic factor in patients with hepatocellular
carcinoma. Int J Biol Markers. 26:108–116. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Ferrara N, Gerber HP and LeCouter J: The
biology of VEGF and its receptors. Nat Med. 9:669–676. 2003.
View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Ren Y, Law S, Huang X, Lee PY, Bacher M,
Srivastava G and Wong J: Macrophage migration inhibitory factor
stimulates angiogenic factor expression and correlates with
differentiation and lymph node status in patients with esophageal
squamous cell carcinoma. Ann Surg. 242:55–63. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Greven D, Leng L and Bucala R: Autoimmune
diseases: MIF as a therapeutic target. Expert Opin Ther Targets.
14:253–264. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Grieb G, Merk M, Bernhagen J and Bucala R:
Macrophage migration inhibitory factor (MIF): a promising
biomarker. Drug News Perspect. 23:257–264. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Meyer-Siegler KL, Iczkowski KA, Leng L,
Bucala R and Vera PL: Inhibition of macrophage migration inhibitory
factor or its receptor (CD74) attenuates growth and invasion of
DU-145 prostate cancer cells. J Immunol. 177:8730–8739. 2006.
View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Ren Y, Chan HM, Fan J, Xie Y, Chen YX, Li
W, Jiang GP, Liu Q, Meinhardt A and Tam PK: Inhibition of tumor
growth and metastasis in vitro and in vivo by targeting macrophage
migration inhibitory factor in human neuroblastoma. Oncogene.
25:3501–3508. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Ren Y, Tsui HT, Poon RT, Ng IO, Li Z, Chen
Y, Jiang G, Lau C, Yu WC, Bacher M and Fan ST: Macrophage migration
inhibitory factor: roles in regulating tumor cell migration and
expression of angiogenic factors in hepatocellular carcinoma. Int J
Cancer. 107:22–29. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Yang XW, Zhang LJ, Huang XH, Chen LZ, Su
Q, Zeng WT, Li W and Wang Q: miR-145 suppresses cell invasion in
hepatocellular carcinoma cells: miR-145 targets ADAM17. Hepatol
Res. Apr 28–2013.(Epub ahead of print). View Article : Google Scholar
|
|
19
|
Namisaki T, Yoshiji H, Noguchi R, Ikenaka
Y, Kitade M, Kaji K, Shirai Y, Aihara Y, Yoshii J, Yanase K,
Tsujimoto T, Kawaratani H and Fukui H: The vascular endothelial
growth factor (VEGF) receptor-2 is a major regulator of
VEGF-mediated salvage effect in murine acute hepatic failure. J
Angiogenes Res. 2:162010. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Hu J, Chen C, Su Y, Du J, Qian X and Jin
Y: Vascular endothelial growth factor promotes the expression of
cyclooxygenase 2 and matrix metalloproteinases in Lewis lung
carcinoma cells. Exp Ther Med. 4:1045–1050. 2012.PubMed/NCBI
|
|
21
|
Li C, Liu B, Dai Z and Tao Y: Knockdown of
VEGF receptor-1 (VEGFR-1) impairs macrophage infiltration,
angiogenesis and growth of clear cell renal cell carcinoma (CRCC).
Cancer Biol Ther. 12:872–880. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Yu W, Chen L, Yang YQ, Falck JR, Guo AM,
Li Y and Yang J: Cytochrome P450 ω-hydroxylase promotes
angiogenesis and metastasis by upregulation of VEGF and MMP-9 in
non-small cell lung cancer. Cancer Chemother Pharmacol. 68:619–629.
2011.
|
|
23
|
Amano H, Ito Y, Suzuki T, Kato S, Matsui
Y, Ogawa F, Murata T, Sugimoto Y, Senior R, Kitasato H, Hayashi I,
Satoh Y, Narumiya S and Majima M: Roles of a prostaglandin E-type
receptor, EP3, in upregulation of matrix metalloproteinase-9 and
vascular endothelial growth factor during enhancement of tumor
metastasis. Cancer Sci. 100:2318–2324. 2009. View Article : Google Scholar
|
|
24
|
Deng G, Zhao DL, Li GC, Yu H and Teng GJ:
Combination therapy of transcatheter arterial chemoembolization and
arterial administration of antiangiogenesis on VX2 liver tumor.
Cardiovasc Intervent Radiol. 34:824–832. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Janani P, Sivakumari K, Geetha A, Yuvaraj
S and Parthasarathy C: Bacoside A downregulates matrix
metalloproteinases 2 and 9 in DEN-induced hepatocellular carcinoma.
Cell Biochem Funct. 28:164–169. 2010. View
Article : Google Scholar : PubMed/NCBI
|
|
26
|
David JR: Delayed hypersensitivity in
vitro: its mediation by cell-free substances formed by lymphoid
cell-antigen interaction. Proc Natl Acad Sci USA. 56:72–77. 1966.
View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Chesney J, Metz C, Bacher M, Peng T,
Meinhardt A and Bucala R: An essential role for macrophage
migration inhibitory factor (MIF) in angiogenesis and the growth of
a murine lymphoma. Mol Med. 5:181–191. 1999.PubMed/NCBI
|
|
28
|
He XX, Yang J, Ding YW, Liu W, Shen QY and
Xia HH: Increased epithelial and serum expression of macrophage
migration inhibitory factor (MIF) in gastric cancer: potential role
of MIF in gastric carcinogenesis. Gut. 55:797–802. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Bando H, Matsumoto G, Bando M, Muta M,
Ogawa T, Funata N, Nishihira J, Koike M and Toi M: Expression of
macrophage migration inhibitory factor in human breast cancer:
association with nodal spread. Jpn J Cancer Res. 93:389–396. 2002.
View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Choudhary S, Hegde P, Pruitt JR, Sielecki
TM, Choudhary D, Scarpato K, Degraff DJ and Pilbeam CC: Macrophage
migratory inhibitory factor promotes bladder cancer progression via
increasing proliferation and angiogenesis. Carcinogenesis. Aug
2–2013.(Epub ahead of print).
|
|
31
|
Bondza PK, Metz CN and Akoum A: Macrophage
migration inhibitory factor up-regulates alpha(v)beta(3) integrin
and vascular endothelial growth factor expression in endometrial
adenocarcinoma cell line Ishikawa. J Reprod Immunol. 77:142–151.
2008. View Article : Google Scholar
|
